Bank of New York Mellon Corp Has $4.85 Million Stock Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Bank of New York Mellon Corp raised its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 0.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 504,007 shares of the company’s stock after buying an additional 3,300 shares during the quarter. Bank of New York Mellon Corp owned about 0.34% of MiMedx Group worth $4,849,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. New York State Common Retirement Fund lifted its stake in shares of MiMedx Group by 93.0% in the fourth quarter. New York State Common Retirement Fund now owns 57,840 shares of the company’s stock valued at $556,000 after buying an additional 27,867 shares during the period. Principal Financial Group Inc. raised its holdings in MiMedx Group by 8.5% in the 4th quarter. Principal Financial Group Inc. now owns 60,226 shares of the company’s stock valued at $579,000 after acquiring an additional 4,731 shares in the last quarter. Palumbo Wealth Management LLC bought a new stake in shares of MiMedx Group in the 4th quarter worth approximately $171,000. Van ECK Associates Corp acquired a new stake in shares of MiMedx Group during the 4th quarter worth approximately $40,000. Finally, Savant Capital LLC bought a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $100,000. 79.15% of the stock is owned by institutional investors.

MiMedx Group Stock Up 1.5 %

MDXG opened at $8.04 on Tuesday. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The firm’s fifty day moving average price is $8.44 and its two-hundred day moving average price is $7.83. The company has a market capitalization of $1.18 billion, a P/E ratio of 14.62 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The firm had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. On average, analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Insiders Place Their Bets

In other news, CAO William Frank Iv Hulse sold 54,596 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the sale, the chief accounting officer now owns 440,178 shares in the company, valued at approximately $3,473,004.42. The trade was a 11.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. This represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 142,259 shares of company stock worth $1,116,170 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.